Floatz logo

Azacitidine

Chondrosarcoma

IGM Biosciences, Inc.Small moleculePhase 1/2Dormant
CCC
55/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
44/ 100
Competitive Position
89/ 100

Competitive context

10 Active assets in the Chondrosarcoma cohort.

Asset / SponsorPhaseRating
ag-120
Memorial Sloan Kettering Cancer Center
Phase 2B
Angiotensin-(1-7)
Wake Forest University Health Sciences
Phase 2CCC
CIS-DIAMMINEDICHLOROPLATINUM II
Eli Lilly and Company
Phase 1/2CCC
Atezolizumab
National Cancer Institute (NCI)
Phase 2CCC
Adapt-001
EpicentRx, Inc.
Phase 2CCC

View all 24 →

Same molecule, other indications

Azacitidine is also rated in:

acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
73 / 100
View asset →
acute erythroid leukemiaDormant
BB
Indicative ·
71 / 100
View asset →
non-small cell lung carcinomaDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →